Innate Pharma (IPHA) Shares Outstanding (Diluted Average) (2018 - 2025)

Innate Pharma (IPHA) has 8 years of Shares Outstanding (Diluted Average) data on file, last reported at $282.99 in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Diluted Average) fell 15.23% year-over-year to $282.99; the trailing twelve-month figure through Jun 2025 stood at $282.99 (down 15.23% YoY), and the FY2018 full-year result was $650.6, changed N/A from the prior year.
• Shares Outstanding (Diluted Average) for Q2 2025 stood at $282.99, down from $333.84 in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $95.1 million in Q2 2021 and bottomed at $21.78 in Q2 2023.
• The 5-year median for Shares Outstanding (Diluted Average) is $282.99 (2025), against an average of $19.0 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Diluted Average) jumped 66439666.22%; it then tumbled 100.0% in 2022.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $95.1 million in 2021, then sank by 100.0% to $85.36 in 2022, then sank by 74.49% to $21.78 in 2023, then jumped by 1432.87% to $333.84 in 2024, then fell by 15.23% to $282.99 in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $282.99 (Q2 2025), $333.84 (Q2 2024), and $21.78 (Q2 2023), per Business Quant data.

Peer Comparison